StockData
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.04+0.03 (+2.97%)

Close on Nov 18, 2026Market cap $13.87MP/E –Yield 0.00%

Tvardi Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Tvardi Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$27.21M. For fiscal 2025 it was -$26.75M. The highest annual figure on record is $5.39M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.75M–
FY2024Dec 31, 2024-$28.11M–
FY2023Dec 31, 2023-$121.50M–
FY2022Dec 31, 2022-$87.54M–
FY2021Dec 31, 2021-$89.08M-1754.3%
FY2020Dec 31, 2020$5.39M–
FY2019Dec 31, 2019-$111.68M–
FY2018Dec 31, 2018-$77.38M–
FY2017Dec 31, 2017-$59.49M–
FY2016Dec 31, 2016-$58.40M–
FY2015Dec 31, 2015-$25.19M–
FY2014Dec 31, 2014-$18.07M–
FY2013Dec 31, 2013-$237.00K–
FY2012Dec 31, 2012-$6.24M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.63M–
Q1 FY2026Mar 31, 2026-$7.05M–
Q4 FY2025Dec 31, 2025-$7.59M–
Q3 FY2025Sep 30, 2025-$5.94M–
Q2 FY2025Jun 30, 2025-$8.87M–
Q1 FY2025Mar 31, 2025-$4.35M–
Q4 FY2024Dec 31, 2024-$10.80M–
Q3 FY2024Sep 30, 2024-$5.68M–
Q2 FY2024Jun 30, 2024-$7.18M–
Q1 FY2024Mar 31, 2024-$29.67M–
Q4 FY2023Dec 31, 2023-$32.61M–
Q3 FY2023Sep 30, 2023-$28.90M–
Q2 FY2023Jun 30, 2023-$32.34M–
Q1 FY2023Mar 31, 2023-$27.65M–
Q4 FY2022Dec 31, 2022-$31.31M–
Q3 FY2022Sep 30, 2022-$23.85M–
Q2 FY2022Jun 30, 2022-$4.47M–
Q1 FY2022Mar 31, 2022-$27.91M–
Q4 FY2021Dec 31, 2021-$33.52M-142.8%
Q3 FY2021Sep 30, 2021-$1.12M–
Q2 FY2021Jun 30, 2021-$30.88M–
Q1 FY2021Mar 31, 2021-$23.56M–
Q4 FY2020Dec 31, 2020$78.29M–
Q3 FY2020Sep 30, 2020-$17.02M–
Q2 FY2020Jun 30, 2020-$25.88M–
Q1 FY2020Mar 31, 2020-$30.00M–
Q4 FY2019Dec 31, 2019-$29.97M–
Q3 FY2019Sep 30, 2019-$34.43M–
Q2 FY2019Jun 30, 2019-$24.14M–
Q1 FY2019Mar 31, 2019-$23.13M–
Q4 FY2018Dec 31, 2018-$21.98M–
Q3 FY2018Sep 30, 2018-$20.47M–
Q2 FY2018Jun 30, 2018-$17.81M–
Q1 FY2018Mar 31, 2018-$17.12M–
Q4 FY2017Dec 31, 2017-$14.57M–
Q3 FY2017Sep 30, 2017-$12.96M–
Q2 FY2017Jun 30, 2017-$9.63M–
Q1 FY2017Mar 31, 2017-$22.33M–
Q4 FY2016Dec 31, 2016-$22.32M–
Q3 FY2016Sep 30, 2016-$11.77M–

More Tvardi Therapeutics figures

See a number that looks wrong?